This study examined the ef®cacy of trazodone 200 mgaday in patients with erectile dysfunction (ED) without major organic ®ndings.
Introduction
In depressed patients using trazodone as an oral antidepressant several case reports have been published reporting uncommon sexual side-effects including penis elongation, 1 orgasmic inhibition, 2 spontaneous orgasms, 3 clitoral priapism 4 and increased libido. 5, 6 However, the most frequently reported sexual side-effects of trazodone use are prolonged erections and priapism. Priapism was reported in at least 200 subjects treated for (mild) depression with age ranging from 24 to 61 y. They all received doses of 50 ± 600 mgaday for 6 days to 4 weeks. 7 The incidence of trazodone-induced priapism was estimated as between 1a6000 and 1a10,000. 3 These anecdotal reports suggest that trazodone seems to have an ability to in¯uence erectile function.
Some studies have focused on the effect of trazodone on penile erection in healthy volunteers 7, 8 and others on men with erectile dysfunction. 9 ± 14 Further studies have yielded information on the mechanism by which trazodone affects penile activity. 7, 15, 16 Trazodone seems to possess an ability to enhance penile erectile activity due to its alphaadrenoceptor blocking activity, which locally interferes with the sympathetic control of penile detumescence. 7 Apart from this effect on erectile function, trazodone has been suggested as a treatment option for loss of libido in some case reports. 5, 6 The Rigiscan Plus 1 has been used to measure the in¯uence of trazodone on nocturnal penile erectile activity in several studies in both healthy volunteers and patients with erectile dysfunction. Saenz de Tejada monitored the sleep-related erections in healthy volunteers in a double-blind crossover study comparing the effects of trazodone, trimipramine and placebo. 7 This study demonstrates that oral trazodone signi®cantly prolonged the duration of sleep-related penile erections. This result was replicated by Ware et al 8 who compared nefazodone, trazodone and buspirone in a double-blind, placebo-controlled crossover study in healthy men.
Both authors suggested that the enhancement of sleep-related penile tumescence by trazodone can be explained by delaying the onset of detumescence. Chiang 10 administered 150 mg trazodone to 14 organic impotent patients in a 5-night single blind design. 16 Analysis of the Rigiscan Plus 1 -results revealed that trazodone caused a signi®cant increase in total erection time and maximum rigidity of erections during sleep and in percentage of sleep with erection. Chiang concluded that oral trazodone can signi®cantly prolong the duration of sleeprelated penile erection. In the same article they reported a 5 week single-blind treatment study in which questionnaires were given before, after 1 and after 5 weeks of treatment. In 69% of patients receiving trazodone, substantial improvement in patients' subjective feelings of improvement of erectile functioning were observed in comparison to 11% in the placebo group. Meinhardt et al 14 reported a double-blind, placebo-controlled trial to assess the ef®cacy of 150 mgaday oral trazodone for treatment of erectile dysfunction with or without organic ®ndings, and did not ®nd trazodone to be more effective than placebo using questionnaires or using the Rigiscan Plus 1 -device.
In a two-centre, prospective, double-blind, placebo-controlled, parallel group study our main objective was to assess the effects of trazodone on erectile function in patients with erectile dysfunction without major organic ®ndings. Secondly, the evolution of the patients' sexual desire was studied.
Subjects, study design and methods

Subjects
Patients were recruited in the out-patient andrology clinic of the University Hospital in Louvain. Thirtynine patients were considered for inclusion, of whom 34 were randomized: 16 to trazodone and 17 to placebo. Inclusion criteria were male patients (18 ± 65 y) with a stable heterosexual relationship for at least 6 months with diagnosed erectile disorder (as de®ned by DSM-IV) longer than 4 months. Exclusion criteria were erectile dysfunction caused by sickle cell anaemia and trait, by thyroid or endocrine disorders (except diabetes; only one patient had diabetes type 2), by spinal cord lesion or pelvic surgery or trauma, history of myocardial infarct coronary angioplasty or coronary bypass graft in the past 3 months (except anti-hypertensive drugs since 2 months before the onset of erectile dysfunction; only one patient was on anti-hypertensive drugs), or ejaculation disorder and medication known to possibly cause erectile dysfunction. Prior to the study written informed consent and approval by the ethics committee were obtained. One patient was excluded from the analyses because he was found to have taken trazodone although he was randomized in the placebo group.
Aim and design of the study
The aim of the present study was to determine whether trazodone as compared to placebo has an effect on erectile functioning in men with diagnosed erectile dysfunction. Therefore, the primary endpoint of this study was the difference in total erection duration over two consecutive nights (with erection de®ned as rigidity exceeding 60% at the base) before and after the double-blind phase in either group and between both groups.
This study contained a 2 week treatment-free, baseline period after which eligible patients entered a 4 week placebo-controlled treatment phase. In patients on treatment, the dose of trazodone was increased to 200 mg once a day taken in the evening. In case of adverse events the daily dose was reduced to 150 mg.
Assessments were done before and at the end of the treatment phase. Intermediary visits assessed the patient's compliance with the study protocol. During the entire study period patients ®lled in a diary to assess their sexual experiences.
Instruments
The effect of trazodone on nocturnal penile activity was measured by means of a nocturnal penile rigidity and tumescence monitoring (Rigiscan Plus 1 ) performed at home for 3 (at least 2) consecutive nights before the beginning and at the end of the treatment phase. Twenty-three patients completed 6 nights, 4 patients completed 5 nights, one patient 4 and one only 3 nights with the Rigiscan Plus 1 . Since it has been shown that there is no ®rst night effect and that 2 or 3 nights are needed to characterize a subject adequately, 17 we performed statistical analyses on 14 patients randomized to trazodone and 14 to placebo with a minimum if two nights before and and two nights after the treatment phase.
The effect of trazodone on sexual desire was measured by different psychometric tests. The derogatis sexual functioning inventory (DSFI) measures subjective feelings about the patient's sexual function. The data taken from the diaries included a visual analogue scale (VAS) for sexual desire (including sexual thoughts, fantasies and desire for coitus), presence of morning erections, and sexual satisfaction. The dyadic adjustment scale (DAS) assessed the quality of the partner relationship and Effects of trazodone P Enzlin et al the Hamilton depression rating scale (HDRS) was used to measure depressive symptoms.
Compliance was assessed with trazodone serum concentrations after 1 week of treatment and at the end of the study. An intake of 150 ± 200 mg trazodone normally results in steady serum concentrations of 575 AE 121 ngaml; good or poor compliance was de®ned as trazodone concentrations higher or lower than 454 ngaml (meanÀ1 s.d.) 18 respectively.
Statistical analysis
Data analysis was performed with the software package SPSS for Windows 8.0. No power calculations were performed before this study started because no trials were found in the literature with comparable endpoints on which estimation of the magnitude of the effect size when comparing trazodone to placebo could be based. Due to small sample size non-parametric tests (Mann ± Whitney U (MW), Wilcoxon signed ranks test (Wilcoxon), and Fischer's exact test (FEt)) were used to compare means. The signi®cance level used was 0.05.
Results
Baseline comparison
Age was not different between placebo and the active drug group, 46 AE 8 y compared to 49 AE 11 y (P`0.11). At baseline there were no signi®cant differences for erection duration (base and tip) and tumescence (base and tip) as measured with the Rigiscan Plus 1 .
However, there were two differences between the groups. First, the mean desire score measured with a VAS was 27 AE 16 in the placebo group compared to 44 AE 22 in the trazodone group (P`0.04). Second, the number of patients reporting the occurrence of morning erections was 45% in the trazodone group and 27% in the placebo group (FEt: P`0.00), but the frequency of these morning erections (numbera week) during the baseline period was not signi®cantly different (P`0.83).
Results at the end of the study Ef®cacy analysis. No signi®cant differences in total erection duration (erection de®ned as rigidity exceeding 60% at the base) before and after the double-blind phase were found in either group (Wilcoxon, trazodone (Trz): P 0.10 and placebo (Plc) P 0.83), and there were also no signi®cant changes within the groups ( Table 1 ). The only change in Rigiscan Plus 1 parameters between baseline and after 4 weeks of treatment was that the erection time (with a rigidity of at least 60%) increased to 8 min 33 s in the trazodone group and 2 min 37 s in the placebo group.
Moreover, no signi®cant differences in the secondary measures of nocturnal erection (total erection duration at tip, mean tumescence at base or tip) before and after the double-blind phase were found in either group (Wilcoxon, Trz P 0.32 and Plc P 0.78; Trz P 0.08 and Plc P 0.49; Trz P 0.57 and Plc P 0.95) and there were also no signi®cant changes within the groups (Table 1) .
Evolution of mean daily sexual desire. No signi®-cant differences in mean daily sexual desire (as measured with a VAS) between the baseline period and the double-blind phase were found in either group (Wilcoxon; Trz P 0.98 and Plc 0.07).
Evolution of morning erections. There was a different change in the number of patients reporting morning erections in both groups. In the trazodone group, morning erections were reported in 45% of the patients during the baseline period and in 47% of the patients during the treatment phase (FEt: Effects of trazodone P Enzlin et al P 0.89). In the placebo group, morning erections were reported in 27% of the patients during the baseline period and in 46% of the patients during the treatment phase (FEt: P 0.01). There was no signi®cantly different change in the frequency of reported morning erections (numberaweek) between both groups.
Psychometric scales
No signi®cant differences in DSFI (total score) or in DAS score before and after the double-blind phase were found in either group (Wilcoxon, Trz P 0.13 and 0.42; Plc P 0.07 and 0.98) and there were also no signi®cant changes between the groups (Wilcoxon; D DSFI P 0.09; D DAS P 0.56). The only signi®cant difference was in the change of the HDRS from before to after the double-blind phase: it changed from 5.2 AE 2.7 to 3.2 AE 1.6 in the trazodone group, while it changed from 3.4 AE 2.9 to 4.4 AE 2.8 in the placebo group (P`0.02).
Compliance
After 1 week of treatment and at the end of the study period patient compliance was assessed by measuring trazodone serum levels. The results are shown in Table 2 . The mean trazodone serum concentration decreased from 620 to 479 ngaml over the four treatment weeks. When using a serum concentration of 454 ngaml to divide patients with a good or a poor compliance, we found that 10 out of 14 patients had good compliance after 1 week of treatment and eight out of 14 patients had good compliance after 4 weeks of treatment (Table 2) . Moreover, the decrease in serum concentration was smaller in patients with a higher satisfaction with their sexual function at the beginning and at the end of the study (r 0.49 and 0.60; P 0.09 and 0.03, respectively). Interesting differences were also found between more or less compliant patients. Signi®cantly lower trazodone concentrations after 1 week of treatment (poor compliance) were found in patients with a better quality of relationship (as assessed with the DAS), with a higher frequency of sexual interaction (including kissingahugging, sexual fantasies, masturbation and coitus) and with a higher sexual desire (as assessed with the mean daily VAS per week during the whole study period, r À0.44, À0.54, À0.67, À0.69, À0.64, À0.70, À0.55; P 0.02, 0.04, 0.009, 0.006, 0.01, 0.005, 0.04, respectively).
Signi®cantly higher trazodone concentrations after 4 weeks of treatment (with good compliance) were found in patients with a higher satisfaction with their sexual function at the beginning and at the end of the study (r 0.48 and 0.56; P 0.09 and 0.04, respectively).
Discussion
The major ®nding in this study was that the only change in Rigiscan Plus 1 parameters between baseline and after 4 weeks of treatment was that the erection time (with a rigidity of 60 ± 100%) increased somewhat in both the trazodone group and the placebo group. However, this change did not reach statistical signi®cance. This result is somewhat half-way between the contradictory ®ndings previously published.
On one hand, Meinhardt et al also did not ®nd signi®cant differences on NPTR measurements between placebo and trazodone users. 14 However, there were some important differences with the present study. First, Meinhardt included older patients (mean age 55 y vs 48 in our study). Second, the included patients with and without organic ®ndings, while the present study included only patients without organic ®ndings. Third, the number of patients for which NPTR data were available was smaller in the Meinhardt study (15 vs 28 in our study). Fourth, the NPTR data in the Meinhardt study were interpreted subjectively by three authors, while they were analysed in a more exact, computerized way in our study.
Saenz de Tejada et al and Ware et al did ®nd a signi®cant increase of duration of nocturnal erection, but they included a smaller number of younger men without erectile dysfunction. 7, 8 It can indeed not be excluded that the effect of trazodone is different in subjects without erectile dysfunction than in patients with erectile dysfunction with or without organic ®ndings. Chiang et al also found a signi®cant increase of total erection time and maximum rigidity of nocturnal erections in patients with clearly organic aetiology, but he used a different methodology: a 5 night single-blind design. 10 Therefore, results cannot be totally compared. It is important to mention that dosage Table 2 Trazodone concentration in ngaml after 1 and 4 weeks treatment   Patient  2  4  5  6  12  14  19  21  22  23  24  31  34  40   1 week  713  693  260  732  517  939  405  249  459  603  394  946  885  886  4 weeks  680  82  127  555  404  49  749  350  245  730  642  571  844  675 Effects of trazodone P Enzlin et al of trazodone cannot be the cause for these contradictions since in all these studies the effectiveness of 100 ± 200 mg trazodone was assessed. Although there was no signi®cantly different change in the frequency of reported morning erections (numberaweek) in both groups, there was an important difference in the change in the number of patients reporting morning erections. In the trazodone group, there was a change from 45% to 47% of the patients reporting morning erections as opposed to a shift from 27% to 46% in the placebo group. One explanation for this ®nding could be a ceiling-effect; indeed, we could speculate that in a group of men with a mean age of 48 y, not more than 45 ± 50% will report morning erections daily.
Anyhow, the present data at least suggest that, as opposed to most other antidepressants (tricyclics, monoamine oxydase inhibitors, selective serotonin reuptake inhibitors), trazodone has no negative impact on sexual function, at least in patients with erectile dysfunction. 19 No signi®cant differences were found in the evolution of the psychometric scales (DSFI, DAS), except for the HDRS. The mean scores on the HDRS of the trazodone group decreased from 5.8 to 3.6 and increased from 3.5 to 4.4 in the placebo group. Although this difference is statistically signi®cant (P`0.01), it is clinically negligible because all these scores are well within the non-depressed range.
The most interesting ®nding in the present study is the poor compliance of the investigated subjects: only 71.4% (10a14) and 57.1% (8a14) showed acceptable compliance after 1 and 4 weeks of treatment, respectively. The mean trazodone serum concentration decreased and the number of poorly compliant patients increased during the study. This is in accordance with the literature where a trend towards decreasing compliance was also found in acute treatment. 20 Moreover, compliance is known to be better when there is a close relationship between drug intake and ef®cacy, which was not the case in our study (K Demyttenaere, unpublished observations). The lack of overall ef®cacy found in this study could have impaired compliance.
Patients with a higher satisfaction with their sexual functioning had a smaller worsening of their compliance between begining and end of the study. This suggests that subjective satisfaction measures are probably more important than objective ef®cacy measures in predicting compliance. The ®nding that patients with a higher satisfaction presented higher trazodone concentrations at the end of the study can be interpreted in the same way.
Signi®cantly lower initial trazodone concentrations were found in patients with a better overall quality of relationship, with a higher sexual desire and with a higher score on frequency of different intimate behaviours, including kissingahugging, fantasies, masturbation and coitus. These are to the best of our knowledge the ®rst published data suggesting that psychological characteristics at least partly determine which patients with erectile dysfunction are compliant or not with oral medication. We hypothesize that patients with a better quality of relationship, with a higher desire for sexual interaction and with a broader range of sexual activities (not only intercourse focused) are less convinced of a pharmacological therapy and are therefore less compliant. It is indeed our clinical impression that patients with erectile dysfunction attending a urology clinic or a sexology clinic have different representations and beliefs on the etiology of their problem and hence on which therapy could be helpful. While the former generally have more mechanistic representations and hence expect more external help (eg medication), the latter generally have more psychosomatic representations and hence expect more internal help (eg psychotherapy).
The signi®cant correlations between serum concentrations and psychometric characteristics do suggest that the variance in concentrations is the consequence of poor compliance rather than of a variance in intestinal absorption.
The present study had a major limitation: the sample size was too small and this had several consequences. The ®rst consequence is that the two groups were signi®cantly different at baseline for some crucial variables Ð mean sexual desire score and number of patients reporting morning erections. A second consequence could be that a possible effect of trazodone was clouded by these baseline differences. Indeed, no signi®cant differences were found between placebo and trazodone and this could be due to several reasons: (a) the fact that the sample size was too small; (b) the fact that patients were non-compliant in drug intake and in Rigiscan Plus 1 measurements: andaor (c) the fact that trazodone is ineffective in the treatment of erectile dysfunction or signi®cant effects were insigni®cant. Anyhow, this does suggest that the magnitude of a potential effect of trazodone on erectile dysfunction is rather small.
In conclusion, the present study did not reveal any signi®cant difference in erection time or sexual desire or other psychological parameters between trazodone and placebo. This result could be due or to a major limitation of the study (small sample size) andaor to the ineffectiveness of trazodone in treating patients with erectile dysfunction andaor to non-compliance. The most important ®ndings in the present study are: (a) trazodone had no effects on sexual function of patients with ED without organic ®ndings; and (b) that poor compliance was found to be a major problem and was linked to speci®c psychological characteristics. Therefore, we suggest that compliance issues should be taken into account in future studies investigating treatment of erectile dysfunction with oral medication.
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